Endotypes and asthma

Clinical Asthma: Theory and Practice

Volumn , Issue , 2014, Pages 29-43

  Haldar, Pranabashis ^a   Berair, Rachid ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84906051619     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b16468     Document Type: Chapter

References (56)

1. Rackemann F. A working classification of asthma. Am J Med 1947;3(5):601-606.
2. British Thoracic Society Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma. Thorax 2008;63(Suppl 4):iv1-iv121.
3. Harrison BD. Psychosocial aspects of asthma in adults. Thorax 1998;53(6):519-525.
4. Anderson GP. Endotyping asthma: New insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 2008;372(9643):1107-1119.
5. Rackemann FM. Studies in asthma: A clinical survey of 1074 patients with asthma followed for 2 years. J Lab Clin Med 1927;12:1185-1197.
6. Rackemann FM. Intrinsic asthma. Postgrad Med 1950;8(2):134-140.
7. Sneath PH, Sokal RR. Numerical taxonomy. Nature 1962;193:855-860.
8. Chen JJ, Roberson PK, Schell MJ. The false discovery rate: A key concept in large-scale genetic studies. Cancer Control 2010;17(1):58-62.
9. Rosi E, Ronchi MC, Grazzini M, et al. Sputum analysis, bronchial hyperresponsiveness, and airway function in asthma: Results of a factor analysis. J Allergy Clin Immunol 1999;103(2 Pt 1):232-237.
10. Everitt BS, Landau S, Leese M. Cluster Analysis, 4th edn. London: Arnold, 2001.
11. Formann AK, Kohlmann T. Latent class analysis in medical research. Stat Methods Med Res 1996;5(2):179-211.
12. Paykel ES. Classification of depressed patients: A cluster analy-sis derived grouping. Brit J Psychiat 1971;118(544):275-288.
13. Kurz A, Moller HJ, Baindl G, et al. Classification of para-suicide by cluster analysis. Types of suicidal behaviour, therapeutic and prognostic implications. Brit J Psychiat 1987;150:520-525.
14. Hawkins GA, Weiss ST, Bleecker ER. Clinical conse-quences of ADRbeta2 polymorphisms. Pharmacogenomics 2008;9(3):349-358.
15. Klotsman M, York TP, Pillai SG, et al. Pharmacogenetics of the 5-lipoxygenase biosynthetic pathway and variable clinical response to montelukast. Pharmacogenet Genom 2007;17(3):189-196.
16. Spanevello A, Confalonieri M, Sulotto F, et al. Induced spu-tum cellularity. Reference values and distribution in nor-mal volunteers. Am J Respir Crit Care Med 2000;162(3 Pt 1):1172-1174.
17. Woodruff PG, Boushey HA, Dolganov GM, et al. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc Natl Acad Sci USA 2007;104(40):15858-15863.
18. Park SW, Jangm HK, An MH, et al. Interleukin-13 and interleukin-5 in induced sputum of eosinophilic bronchitis: Comparison with asthma. Chest 2005;128(4):1921-1927.
19. Szefler SJ, Martin RJ, King TS, et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol 2002;109(3):410-418.
20. Brightling CE, McKenna S, Hargadon B, et al. Sputum eosinophilia and the short term response to inhaled mometa-sone in chronic obstructive pulmonary disease. Thorax 2005;60(3):193-198.
21. Smith AD, Cowan JO, Brassett KP, et al. Exhaled nitric oxide: A predictor of steroid response. Am J Respir Crit Care Med 2005;172(4):453-459.
22. Deykin A, Lazarus SC, Fahy JV, et al. Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids. J Allergy Clin Immunol 2005;115(4):720-727.
23. Pizzichini MM, Pizzichini E, Clelland L, et al. Sputum in severe exacerbations of asthma: Kinetics of inflammatory indices after prednisone treatment. Am J Respir Crit Care Med 1997;155(5):1501-1508.
24. Green RH, Brightling CE, McKenna S, et al. Asthma exac-erbations and sputum eosinophil counts: A randomised con-trolled trial. Lancet 2002;360(9347):1715-1721.
25. Chlumsky J, Striz I, Terl M, et al. Strategy aimed at reduction of sputum eosinophils decreases exacerbation rate in patients with asthma. J Int Med Res 2006;34(2):129-139.
26. Jayaram L, Pizzichini MM, Cook RJ, et al. Determining asthma treatment by monitoring sputum cell counts: Effect on exacerbations. Eur Respir J 2006;27(3):483-494.
27. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360(10):973-984.
28. Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009;360(10):985-993.
29. Leckie MJ, ten Brinke A, Khan J, et al. Effects of an interleu-kin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000;356(9248):2144-2148.
30. Abba AA. Exhaled nitric oxide in diagnosis and man-agement of respiratory diseases. Ann Thorac Med 2009;4(4):173-181.
31. Smith AD, Cowan JO, Brassett KP, et al. Exhaled nitric oxide: A predictor of steroid response. Am J Respir Crit Care Med 2005;172(4):453-459.
32. Pérez-de-Llano LA, Carballada F, Castro Añón O, et al. Exhaled nitric oxide predicts control in patients with difficult-to-treat asthma. Eur Respir J 2010;35(6):1221-1227.
33. Smith AD, Cowan JO, Brassett KP, et al. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005;352(21):2163-2173.
34. Petsky HL, Cates CJ, Lasserson TJ, et al. A systematic review and meta-analysis: Tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax 2012;67:199-208.
35. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): A multicentre, double-blind, placebo-controlled trial. Lancet 2012;380(9842):651-659.
36. Haldar P, Pavord ID. Noneosinophilic asthma: A distinct clinical and pathologic phenotype. J Allergy Clin Immunol 2007;119(5):1043-1052.
37. Green RH, Brightling CE, Woltmann G, et al. Analysis of induced sputum in adults with asthma: Identification of sub-group with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002;57(10):875-879.
38. Gibson PG, Simpson JL, Saltos N. Heterogeneity of airway inflammation in persistent asthma: Evidence of neutrophilic inflammation and increased sputum interleukin-8. Chest 2001;119(5):1329-1336.
39. Douwes J, Gibson P, Pekkanen J, et al. Non-eosinophilic asthma: Importance and possible mechanisms. Thorax 2002;57(7):643-648.
40. Berry M, Morgan A, Shaw DE, et al. Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma. Thorax 2007;62(12):1043-1049.
41. Simpson JL, Scott R, Boyle MJ, et al. Inflammatory subtypes in asthma: Assessment and identification using induced spu-tum. Respirology 2006;11(1):54-61.
42. D’silva L, Cook RJ, Allen CJ, et al. Changing pattern of spu-tum cell counts during successive exacerbations of airway dis-ease. Respir Med 2007;101(10):2217-2220.
43. Gibson PG. Inflammatory phenotypes in adult asthma: Clinical applications. Clin Respir J 2009;3(4):198-206.
44. Wardlaw AJ, Brightling CE, Green R, et al. New insights into the relationship between airway inflammation and asthma. Clin Sci 2002;103(2):201-211.
45. Medzhitov R, Janeway Jr. C. Innate immunity. N Engl J Med 2000;343(5):338-344.
46. Johnston SL, Pattemore PK, Sanderson G, et al. Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. BMJ 1995;310(6989):1225-1229.
47. Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008;178(3):218-224.
48. Pavord ID, Brightling CE, Woltmann G, et al. Non-eosinophilic corticosteroid unresponsive asthma. Lancet 1999;353(9171):2213-2214.
49. Simpson JL, Powell H, Boyle MJ, et al. Clarithromycin tar-gets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med 2008;177(2):148-155.
50. Cymbala AA, Edmonds LC, Bauer MA, et al. The disease-mod-ifying effects of twice-weekly oral azithromycin in patients with bronchiectasis. Treat Respir Med 2005;4(2):117-122.
51. Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010;181(4):315-323.
52. Miranda C, Busacker A, Balzar S, et al. Distinguishing severe asthma phenotypes: Role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol 2004;113(1):101-108.
53. Kikuchi Y, Okabe S, Tamura G, et al. Chemosensitivity and perception of dyspnea in patients with a history of near-fatal asthma. N Engl J Med 1994;330(19):1329-1334.
54. Rasmussen F, Hancox RJ, Nair P, et al. Associations between airway hyperresponsiveness, obesity, and lipoproteins in a longitudinal cohort. Clin Respir J 2012;7(3):268-275.
55. Sideleva O, Suratt BT, Black KE, et al. Obesity and asthma: An inflammatory disease of adipose tissue not the airway. Am J Respir Crit Care Med 2012;186(7):598-605.
56. Dixon AE, Pratley RE, Forgione PM, et al. Effects of obe-sity and bariatric surgery on airway hyperresponsiveness, asthma control, and inflammation. J Allergy Clin Immunol 2011;128(3):508-515.